Login Register Cart 0
Generic placeholder image

Current Nanomedicine

Editor-in-Chief

ISSN (Print): 2468-1873
ISSN (Online): 2468-1881

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Nanotechnology in Drug Delivery: Overcoming Poor Solubility Challenges through Nanoformulations

Author(s): Atul Chaudhary* and Sharda Shambhakar

Volume 14, Issue 3, 2024

Published on: 19 January, 2024

Page: [200 - 211] Pages: 12

DOI: 10.2174/0124681873276732231207051324

Price: $65

conference banner
Abstract

The pharmaceutical sector continues to face difficulties with poorly soluble drug solubility. Insufficiently soluble drugs have low bioavailability, and their effectiveness is frequently affected. Numerous approaches have been developed in response to this challenge, including using various dosage forms, solid dispersions, nano-suspensions, self-emulsifying drug delivery systems, and cyclodextrin complexes. By improving drug dissolving, decreasing drug particle size, and increasing drug dispersion, these dosage forms seek to increase drug solubility. Nanotechnology is one of the latest advances that has the potential to revolutionize the delivery of drugs and significantly improve the solubility of drugs that are now poorly soluble. Since they have a larger surface area and can pass through biological barriers, nanoparticles are particularly well suited for the delivery of drugs. These technologies can potentially enable the development of more effective and efficient drug formulations for the treatment of various diseases. In addition, the review highlights recent advances in the field, including emerging technologies such as nanotechnology, which can revolutionize drug delivery and significantly improve the solubility of poorly soluble drugs with their potential applications.

Keywords: Bioavailability, cyclodextrin, liposomes, nanoparticles, solubility, suspension.

« Previous Next »
Graphical Abstract

[1]
Kumari L, Choudhari Y, Patel P, et al. Advancement in solubilization approaches: A step towards bioavailability enhancement of poorly soluble drugs. Life 2023; 13(5): 1099.
[http://dx.doi.org/10.3390/life13051099] [PMID: 37240744]
[2]
Kumar LA, Pattnaik G, Satapathy BS, Patro CS, Naik S, Dash AK. Solubility enhancement techniques: Updates and prospectives. J Pharm Negat Results 2022; 13: 2847-55.
[3]
Jin Z, Gao Q, Wu K, Ouyang J, Guo W, Liang XJ. Harnessing inhaled nanoparticles to overcome the pulmonary barrier for respiratory disease therapy. Adv Drug Deliv Rev 2023; 202: 115111.
[http://dx.doi.org/10.1016/j.addr.2023.115111] [PMID: 37820982]
[4]
Teixeira MC, Carbone C, Souto EB. Beyond liposomes: Recent advances on lipid based nanostructures for poorly soluble/poorly permeable drug delivery. Prog Lipid Res 2017; 68: 1-11.
[http://dx.doi.org/10.1016/j.plipres.2017.07.001] [PMID: 28778472]
[5]
van der Merwe J, Steenekamp J, Steyn D, Hamman J. The role of functional excipients in solid oral dosage forms to overcome poor drug dissolution and bioavailability In: Pharmaceutics Multidisciplinary digital publishing institute. 2020; 12: p. (5)393.
[http://dx.doi.org/10.3390/pharmaceutics12050393]
[6]
Balk A, Wiest J, Widmer T, Galli B, Holzgrabe U, Meinel L. Transformation of acidic poorly water soluble drugs into ionic liquids. Eur J Pharm Biopharm 2015; 94: 73-82.
[http://dx.doi.org/10.1016/j.ejpb.2015.04.034] [PMID: 25976317]
[7]
Khadka P, et al. Pharmaceutical particle technologies: An approach to improve drug solubility, dissolution and bioavailability In: Asian Journal of Pharmaceutical Sciences. Elsevier 2014; 9: pp. (6)304-16.
[http://dx.doi.org/10.1016/j.ajps.2014.05.005]
[8]
Kumar S, Singh P. The Pharma Innovation Journal 2016; 5(1): 23-28 Various techniques for solubility enhancement: An overview 2016. Available from: www.thepharmajournal.com Accessed: Mar. 17, 2023. [Online].
[9]
Mishra S, Verma P, Gupta S, Pandey S, Ojha S. Nanocarrier and herbal based transdermal patch: An advantage over other drug delivery systems In: Ann Ayurvedic Med. 2022; pp. 145-56.
[http://dx.doi.org/10.5455/AAM.11486]
[10]
Asim M, Nazir M, Chauhdary Z, et al. Enhanced solubility and biological activity of dexibuprofen-loaded silica-based ternary solid dispersions. Pharmaceutics 2023; 15(2): 399.
[http://dx.doi.org/10.3390/pharmaceutics15020399] [PMID: 36839721]
[11]
Jaiswal P, Mishra A, Kesharwani D, Das Paul S. Overview on ocular drug delivery through colloidal nano-suspension. Res J Pharm Technol 2023; 16(3): 1533-9.
[http://dx.doi.org/10.52711/0974-360X.2023.00251]
[12]
Kumar A, Sharma S, Kamble R. Self emulsifying drug delivery system (SEDDS): Future aspects. Int J Pharm Pharm Sci 2010; 2 (SUPPL. 4): 7-13.
[13]
Noreen S, Maqbool I, Ijaz M, Tanveer S. Cyclodextrin inclusion complexes: Novel techniques to improve solubility of poorly soluble drugs: A review. Global Pharmaceutical Sciences Review 2016; I(I): 29-34.
[http://dx.doi.org/10.31703/gpsr.2016(I-I).04]
[14]
Kumar S, Dilbaghi N, Saharan R, Bhanjana G. Nanotechnology as emerging tool for enhancing solubility of poorly water-soluble drugs. Bionanoscience 2012; 2(4): 227-50.
[http://dx.doi.org/10.1007/s12668-012-0060-7]
[15]
Satyanarayana SD, Abu Lila AS, Moin A, et al. Ocular delivery of bimatoprost-loaded solid lipid nanoparticles for effective management of glaucoma. Pharmaceuticals 2023; 16(7): 1001.
[http://dx.doi.org/10.3390/ph16071001] [PMID: 37513913]
[16]
Ojha S, Yadav S, Ajeet B, Aggarwal S, Gupta K, Mishra S. Considering the conception of nanotechnology integrated on herbal formulation for the management of cancer. Lett Drug Des Discov 2022; 19.
[http://dx.doi.org/10.2174/1570180819666220901093732]
[17]
Mishra S. Hyperbranched nanostructure drug delivery carrier: Dendrimer. Nanosci Nanotechnol Asia 2023; 13(1): e140223213668.
[http://dx.doi.org/10.2174/2210681213666230214103113]
[18]
Savjani KT, Gajjar AK, Savjani JK. Drug solubility: Importance and enhancement techniques. ISRN Pharm 2012; 2012: 1-10.
[http://dx.doi.org/10.5402/2012/195727] [PMID: 22830056]
[19]
Sharma M, Sharma R, Jain DK. ScientificaNanotechnology Based Approaches for Enhancing Oral Bioavailability of Poorly Water Soluble Antihypertensive Drugs In: Scientifica. Hindawi Limited 2016; p. 2016.
[http://dx.doi.org/10.1155/2016/8525679]
[20]
Mirza RM, Ahirrao SP, Kshirsagar SJ. A nanocrystal technology: To enhance solubility of poorly water soluble drugs. J Appl Pharm Res 2017; 5(1): 1-13. [Online]. [Available: www.japtronline.com
[21]
Singh N, Maurta R, Mishra S, Jain D. Preparation and evaluation of medicated formulation for dry eye. Nanosci Nanotechnol Asia 2023; 13(4): e260523217386.
[http://dx.doi.org/10.2174/2210681213666230526152322]
[22]
Jamekhorshid A, Sadrameli SM, Farid M. A review of microencapsulation methods of phase change materials (PCMs) as a thermal energy storage (TES) medium. Renew Sustain Energy Rev 2014; 31: 531-42.
[http://dx.doi.org/10.1016/j.rser.2013.12.033]
[23]
Rostami E. Progresses in targeted drug delivery systems using chitosan nanoparticles in cancer therapy: A mini-review. J Drug Deliv Sci Technol 2020; 58: 101813.
[http://dx.doi.org/10.1016/j.jddst.2020.101813]
[24]
Conley R, Gupta SK, Sathyan G. Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form. Curr Med Res Opin 2006; 22(10): 1879-92.
[http://dx.doi.org/10.1185/030079906X132613] [PMID: 17022845]
[25]
Padalkar AN, Shahi SR, Thube MW. Microparticles: An approach for betterment of drug delivery systems. Int J Pharm Res Dev 2011; 3: 99-115.
[26]
Tran P, Park JS. Application of supercritical fluid technology for solid dispersion to enhance solubility and bioavailability of poorly water-soluble drugs. Int J Pharm 2021; 610: 121247.
[http://dx.doi.org/10.1016/j.ijpharm.2021.121247] [PMID: 34740762]
[27]
Cui B, Feng L, Wang C, et al. Stability and biological activity evaluation of chlorantraniliprole solid nanodispersions prepared by high pressure homogenization. PLoS One 2016; 11(8): e0160877.
[http://dx.doi.org/10.1371/journal.pone.0160877] [PMID: 27500828]
[28]
Schwendeman SP, Shah RB, Bailey BA, Schwendeman AS. Injectable controlled release depots for large molecules. J Control Release 2014; 190: 240-53.
[http://dx.doi.org/10.1016/j.jconrel.2014.05.057] [PMID: 24929039]
[29]
Sharma A, Jain CP. Solid dispersion: A promising technique to enhance solubility of poorly water soluble drug. Int J Drug Deliv 2011; 1(2): 149-70.
[30]
Konno H, Taylor LS. Ability of different polymers to inhibit the crystallization of amorphous felodipine in the presence of moisture. Pharm Res 2008; 25(4): 969-78.
[http://dx.doi.org/10.1007/s11095-007-9331-3] [PMID: 17520180]
[31]
Sharma KS, Sahoo J, Agrawal S, Kumari A. Solid dispersions: A technology for improving bioavailability. J Anal Pharm Res 2019; 8(4): 127-33.
[http://dx.doi.org/10.15406/japlr.2019.08.00326]
[32]
Aziz T, Ullah A, Ali A, et al. Manufactures of bio‐degradable and bio‐based polymers for bio‐materials in the pharmaceutical field. J Appl Polym Sci 2022; 139(29): e52624.
[http://dx.doi.org/10.1002/app.52624]
[33]
Tran PHL, Tran TTD. Dosage form designs for the controlled drug release of solid dispersions. Int J Pharm 2020; 581: 119274.
[http://dx.doi.org/10.1016/j.ijpharm.2020.119274] [PMID: 32234566]
[34]
Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J Pharm Sci 1996; 85(10): 1017-25.
[http://dx.doi.org/10.1021/js950534b] [PMID: 8897265]
[35]
Del Valle EMM. Cyclodextrins and their uses: A review. Process Biochem 2004; 39(9): 1033-46.
[http://dx.doi.org/10.1016/S0032-9592(03)00258-9]
[36]
Salústio PJ, et al. Advanced technologies for oral controlled release: Cyclodextrins for oral controlled release. AAPS PharmSciTech 2011; 12(4): 1276-92.
[http://dx.doi.org/10.1208/s12249-011-9690-2]
[37]
Jagtap S, Magdum C, Jadge D, Jagtap R. Solubility enhancement technique: A review. Int J Pharm Res 2021; 13(3): 2205-11.
[http://dx.doi.org/10.31838/ijpr/2021.13.03.121]
[38]
Wong J, Brugger A, Khare A, et al. Suspensions for intravenous (IV) injection: A review of development, preclinical and clinical aspects. Adv Drug Deliv Rev 2008; 60(8): 939-54.
[http://dx.doi.org/10.1016/j.addr.2007.11.008] [PMID: 18343527]
[39]
Khan BA, et al. Basics of pharmaceutical emulsions: A review. Afr J Pharm Pharmacol 2011; 5(25): 2715-25.
[http://dx.doi.org/10.5897/AJPP11.698]
[40]
Washington C. Stability of lipid emulsions for drug delivery. Adv Drug Deliv Rev 1996; 20(2-3): 131-45.
[http://dx.doi.org/10.1016/0169-409X(95)00116-O]
[41]
Nsairat H, Khater D, Sayed U, Odeh F, Al Bawab A, Alshaer W. Liposomes: structure, composition, types, and clinical applications. Heliyon 2022; 8(5): e09394.
[http://dx.doi.org/10.1016/j.heliyon.2022.e09394] [PMID: 35600452]
[42]
Coimbra M, Isacchi B, van Bloois L, et al. Improving solubility and chemical stability of natural compounds for medicinal use by incorporation into liposomes. Int J Pharm 2011; 416(2): 433-42.
[http://dx.doi.org/10.1016/j.ijpharm.2011.01.056] [PMID: 21291975]
[43]
Pawar AY, Naik AK, Jadhav KR. Nanosponges: A novel drug delivery system. Asian J Pharm 2016; 10(4): S456-63.
[http://dx.doi.org/10.5958/0975-4377.2020.00043.9]
[44]
Sahu G, Sharma H, Gupta A, Kaur C. Advancements in Microemulsion Based Drug Delivery Systems for Better Therapeutic Effects Int J Pharm Sci Dev Res 2015; 1(1): 8-15.
[http://dx.doi.org/10.17352/ijpsdr.000003]
[45]
He CX, He ZG, Gao JQ. Microemulsions as drug delivery systems to improve the solubility and the bioavailability of poorly water-soluble drugs. Expert Opin Drug Deliv 2010; 7(4): 445-60.
[http://dx.doi.org/10.1517/17425241003596337] [PMID: 20201713]
[46]
Shukla T, Upmanyu N, Agrawal M, Saraf S, Saraf S, Alexander A. Biomedical applications of microemulsion through dermal and transdermal route. Biomed Pharmacother 2018; 108: 1477-94.
[http://dx.doi.org/10.1016/j.biopha.2018.10.021] [PMID: 30372850]
[47]
Jadhav K, Shaikh I, Ambade K, Kadam V. Applications of microemulsion based drug delivery system. Curr Drug Deliv 2006; 3(3): 267-73.
[http://dx.doi.org/10.2174/156720106777731118] [PMID: 16848728]
[48]
Torchilin VP. Micellar nanocarriers: Pharmaceutical perspectives. Pharm Res 2006; 24(1): 1-16.
[http://dx.doi.org/10.1007/s11095-006-9132-0] [PMID: 17109211]
[49]
Jin G, Ngo HV, Cui JH, Wang J, Park C, Lee BJ. Role of surfactant micellization for enhanced dissolution of poorly water‐soluble cilostazol using poloxamer 407‐based solid dispersion via the anti‐solvent method. Pharmaceutics 2021; 13(5): 662.
[http://dx.doi.org/10.3390/pharmaceutics13050662] [PMID: 34063136]
[50]
Vasconcelos T, Sarmento B, Costa P. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov Today 2007; 12(23-24): 1068-75.
[http://dx.doi.org/10.1016/j.drudis.2007.09.005] [PMID: 18061887]
[51]
Rasenack N, Müller BW. Micron-size drug particles: Common and novel micronization techniques. Pharm Dev Technol 2004; 9(1): 1-13.
[http://dx.doi.org/10.1081/PDT-120027417] [PMID: 15000462]
[52]
Saleem IY, Smyth HDC. Micronization of a soft material: Air-jet and micro-ball milling. AAPS PharmSciTech 2010; 11(4): 1642-9.
[http://dx.doi.org/10.1208/s12249-010-9542-5] [PMID: 21107775]
[53]
Sinha B, Müller RH, Möschwitzer JP. Bottom-up approaches for preparing drug nanocrystals: Formulations and factors affecting particle size. Int J Pharm 2013; 453(1): 126-41.
[http://dx.doi.org/10.1016/j.ijpharm.2013.01.019] [PMID: 23333709]
[54]
Huang L, Tong WQ. Impact of solid state properties on developability assessment of drug candidates. Adv Drug Deliv Rev 2004; 56(3): 321-34.
[http://dx.doi.org/10.1016/j.addr.2003.10.007] [PMID: 14962584]
[55]
Raza K. Polymorphism: The phenomenon affecting the performance of drugs. SOJ Pharm Pharm Sci 2014.
[http://dx.doi.org/10.15226/2374-6866/1/2/00111]
[56]
Blagden N, de Matas M, Gavan PT, York P. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. Adv Drug Deliv Rev 2007; 59(7): 617-30.
[http://dx.doi.org/10.1016/j.addr.2007.05.011] [PMID: 17597252]
[57]
Aziz T, et al. Cellulose nanocrystals applications in health, medicine and catalysis In: Journal of Polymers and the Environment. Springer 2021; 29: pp. (7)2062-71.
[http://dx.doi.org/10.1007/s10924-021-02045-1]
[58]
Yu L, Reutzel SM, Stephenson GA. Physical characterization of polymorphic drugs: An integrated characterization strategy. Pharm Sci Technol Today 1998; 1(3): 118-27.
[http://dx.doi.org/10.1016/S1461-5347(98)00031-5]
[59]
Healy AM, Worku ZA, Kumar D, Madi AM. Pharmaceutical solvates, hydrates and amorphous forms: A special emphasis on cocrystals. Adv Drug Deliv Rev 2017; 117: 25-46.
[http://dx.doi.org/10.1016/j.addr.2017.03.002] [PMID: 28342786]
[60]
Lukyanov AN, Torchilin VP. Micelles from lipid derivatives of water-soluble polymers as delivery systems for poorly soluble drugs. Adv Drug Deliv Rev 2004; 56(9): 1273-89.
[http://dx.doi.org/10.1016/j.addr.2003.12.004] [PMID: 15109769]
[61]
Klamt A. Conductor-like screening model for real solvents: A new approach to the quantitative calculation of solvation phenomena. J Phys Chem 1995; 99(7): 2224-35.
[http://dx.doi.org/10.1021/j100007a062]
[62]
Vippagunta SR, Brittain HG, Grant DJW. Crystalline solids. Adv Drug Deliv Rev 2001; 48(1): 3-26.
[http://dx.doi.org/10.1016/S0169-409X(01)00097-7 ] [PMID: 11325474]
[63]
Pasquali I, Bettini R, Giordano F. Supercritical fluid technologies: An innovative approach for manipulating the solid-state of pharmaceuticals. Adv Drug Deliv Rev 2008; 60(3): 399-410.
[http://dx.doi.org/10.1016/j.addr.2007.08.030] [PMID: 17964684]
[64]
Chen H, Khemtong C, Yang X, Chang X, Gao J. Nanonization strategies for poorly water-soluble drugs. Drug Discov Today 2011; 16(7-8): 354-60.
[http://dx.doi.org/10.1016/j.drudis.2010.02.009] [PMID: 20206289]
[65]
Yadav AV, Shete AS, Dabke AP, Kulkarni PV, Sakhare SS. Co-crystals: A novel approach to modify physicochemical properties of active pharmaceutical ingredients. Indian J Pharm Sci 2009; 71(4): 359-70.
[http://dx.doi.org/10.4103/0250-474X.57283] [PMID: 20502540]
[66]
Banerjee R, Bhatt PM, Ravindra NV, Desiraju GR. Saccharin salts of active pharmaceutical ingredients, their crystal structures, and increased water solubilities. Cryst Growth Des 2005; 5(6): 2299-309.
[http://dx.doi.org/10.1021/cg050125l]
[67]
Patole T, Deshpande A. Co-crystallization-a technique for solubility enhancersement. Int J Pharm Sci Res 2014; 5(9): 3566. [Online]. Available:
[http://dx.doi.org/10.13040/IJPSR.0975-8232.5]
[68]
Jana S, Mandlekar S, Marathe P. Prodrug design to improve pharmacokinetic and drug delivery properties: Challenges to the discovery scientists. Curr Med Chem 2010; 17(32): 3874-908.
[http://dx.doi.org/10.2174/092986710793205426] [PMID: 20858214]
[69]
Mahato R, Tai W, Cheng K. Prodrugs for improving tumor targetability and efficiency. Adv Drug Deliv Rev 2011; 63(8): 659-70.
[http://dx.doi.org/10.1016/j.addr.2011.02.002] [PMID: 21333700]
[70]
Rautio J, Meanwell NA, Di L, Hageman MJ. The expanding role of prodrugs in contemporary drug design and development. Nat Rev Drug Discov 2018; 17(8): 559-87.
[http://dx.doi.org/10.1038/nrd.2018.46] [PMID: 29700501]
[71]
Song N-N, Zhang S, Liu C. Overview of factors affecting oral drug absorption Asian J. Drug Metab Pharmacokinet 2004; 4(3): 167-76. [Online]. [Available: http://www.hktmc.com/ChineseMedia/Magazine/Medicine/ajdmpk/AJDMPK-2004-3/asian2004-3(167-176).pdf
[72]
Bassi P, Kaur G. pH modulation: A mechanism to obtain pH-independent drug release. Expert Opin Drug Deliv 2010; 7(7): 845-57.
[http://dx.doi.org/10.1517/17425247.2010.491508] [PMID: 20509776]
[73]
Taniguchi C, Kawabata Y, Wada K, Yamada S, Onoue S. Microenvironmental pH-modification to improve dissolution behavior and oral absorption for drugs with pH-dependent solubility. Expert Opin Drug Deliv 2014; 11(4): 505-16.
[http://dx.doi.org/10.1517/17425247.2014.881798] [PMID: 24472170]
[74]
Schreier S, Malheiros SVP, de Paula E. Surface active drugs: Self-association and interaction with membranes and surfactants. Physicochemical and biological aspects. Biochim Biophys Acta Biomembr 2000; 1508(1-2): 210-34.
[http://dx.doi.org/10.1016/S0304-4157(00)00012-5 ] [PMID: 11090827]
[75]
Kesarwani K, Gupta R, Mukerjee A. Bioavailability enhancers of herbal origin: An overview. Asian Pac J Trop Biomed 2013; 3(4): 253-66.
[http://dx.doi.org/10.1016/S2221-1691(13)60060-X ] [PMID: 23620848]
[76]
Tomita M, Hayashi M, Awazu S. Absorption-enhancing mechanism of EDTA, caprate, and decanoylcarnitine in Caco-2 cells. J Pharm Sci 1996; 85(6): 608-11.
[http://dx.doi.org/10.1021/js9504604] [PMID: 8773957]
[77]
Donnelly A, Kellaway IW, Taylor G, Gibson M. Absorption enhancers as tools to determine the route of nasal absorption of peptides. J Drug Target 1998; 5(2): 121-7.
[http://dx.doi.org/10.3109/10611869808995865] [PMID: 9588868]
[78]
Yang X, Sheng W, Sun GY, Lee JCM. Effects of fatty acid unsaturation numbers on membrane fluidity and α-secretase-dependent amyloid precursor protein processing. Neurochem Int 2011; 58(3): 321-9.
[http://dx.doi.org/10.1016/j.neuint.2010.12.004] [PMID: 21184792]
[79]
Carpentieri-Rodrigues LN, Zanluchi JM, Grebogi IH. Percutaneous absorption enhancers: Mechanisms and potential. Braz Arch Biol Technol 2007; 50(6): 949-61.
[http://dx.doi.org/10.1590/S1516-89132007000700006]
[80]
Yadav A, Tiwari NN, Srivastava SP, Tripathi SM, Mishra S. Bioactive compound containing hepatoprotective activity. Curr Bioact Compd 2023; 19(9): e110423215658.
[http://dx.doi.org/10.2174/1573407219666230411111304]
[81]
Kanwal T, Saifullah S, Rehman J, et al. Design of absorption enhancer containing self-nanoemulsifying drug delivery system (SNEDDS) for curcumin improved anti-cancer activity and oral bioavailability. J Mol Liq 2021; 324: 114774.
[http://dx.doi.org/10.1016/j.molliq.2020.114774]
[82]
Maeda Y, Teraoka H, Okada A, et al. Development and evaluation of EDTA-treated rabbits for bioavailability study of chelating drugs using levofloxacin, ciprofloxacin, hemiacetal ester prodrugs, and tetracycline. Pharmaceutics 2023; 15(6): 1589.
[http://dx.doi.org/10.3390/pharmaceutics15061589 ] [PMID: 37376038]
[83]
SreeHarsha N, Hiremath JG, Chilukuri S, et al. An approach to enhance dissolution rate of tamoxifen citrate. BioMed Res Int 2019; 2019: 1-11.
[http://dx.doi.org/10.1155/2019/2161348] [PMID: 30800663]
[84]
Naik A, Pechtold LARM, Potts RO, Guy RH. Mechanism of oleic acid-induced skin penetration enhancement in vivo in humans. J Control Release 1995; 37(3): 299-306.
[http://dx.doi.org/10.1016/0168-3659(95)00088-7]
[85]
Moghimipour E, Ameri A, Handali S. Absorption-enhancing effects of bile salts. Molecules 2015; 20(8): 14451-73.
[http://dx.doi.org/10.3390/molecules200814451] [PMID: 26266402]
[86]
Sharma P, Varma MVS, Chawla HPS, Panchagnula R. Absorption enhancement, mechanistic and toxicity studies of medium chain fatty acids, cyclodextrins and bile salts as peroral absorption enhancers. Farmaco 2005; 60(11-12): 884-93.
[http://dx.doi.org/10.1016/j.farmac.2005.08.008] [PMID: 16226752]
[87]
Lu Y, Wang YY, Yang N, et al. Food emulsifier polysorbate 80 increases intestinal absorption of di-(2-ethylhexyl) phthalate in rats. Toxicol Sci 2014; 139(2): 317-27.
[http://dx.doi.org/10.1093/toxsci/kfu055] [PMID: 24675089]
[88]
Pershing LK, Lambert LD, Knutson K. Mechanism of ethanol-enhanced estradiol permeation across human skin in vivo. Pharm Res 1990; 7(2): 170-5.
[http://dx.doi.org/10.1023/A:1015832903398] [PMID: 2308897]
[89]
Huriez P, Ourghanlian C, Razazi K, et al. Probenecid, an old β-lactams pharmacokinetic enhancer for a renewed use: A retrospective study. Infectious Diseases Now 2022; 52(5): 273-9.
[http://dx.doi.org/10.1016/j.idnow.2022.05.006] [PMID: 35636701]
[90]
Rengelshausen J, Göggelmann C, Burhenne J, et al. Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin–clarithromycin interaction. Br J Clin Pharmacol 2003; 56(1): 32-8.
[http://dx.doi.org/10.1046/j.1365-2125.2003.01824.x ] [PMID: 12848773]
[91]
Haider M, Abdin SM, Kamal L, Orive G. Nanostructured lipid carriers for delivery of chemotherapeutics: A review. Pharmaceutics 2020; 12(3): 288.
[http://dx.doi.org/10.3390/pharmaceutics12030288 ] [PMID: 32210127]
[92]
Razavi MS, Ebrahimnejad P, Fatahi Y, D’Emanuele A, Dinarvand R. Recent developments of nanostructures for the ocular delivery of natural compounds Front Chem 2022; 10.
[http://dx.doi.org/10.3389/fchem.2022.850757]
[93]
Nirbhavane P, Sharma G, Singh B, et al. Triamcinolone acetonide loaded-cationic nano-lipoidal formulation for uveitis: Evidences of improved biopharmaceutical performance and anti-inflammatory activity. Colloids Surf B Biointerfaces 2020; 190: 110902.
[http://dx.doi.org/10.1016/j.colsurfb.2020.110902] [PMID: 32143010]
[94]
Tatke A, Dudhipala N, Janga K, et al. in situ gel of triamcinolone acetonide-loaded solid lipid nanoparticles for improved topical ocular delivery: Tear kinetics and ocular disposition studies. Nanomaterials 2018; 9(1): 33.
[http://dx.doi.org/10.3390/nano9010033] [PMID: 30591688]
[95]
Desoqi MH, El-Sawy HS, Kafagy E, Ghorab M, Gad S. Fluticasone propionate–loaded solid lipid nanoparticles with augmented anti-inflammatory activity: optimisation, characterisation and pharmacodynamic evaluation on rats. J Microencapsul 2021; 38(3): 177-91.
[http://dx.doi.org/10.1080/02652048.2021.1887383 ] [PMID: 33583315]
[96]
Zhang J, Liu Z, Tao C, et al. Cationic nanoemulsions with prolonged retention time as promising carriers for ophthalmic delivery of tacrolimus. Eur J Pharm Sci 2020; 144: 105229.
[http://dx.doi.org/10.1016/j.ejps.2020.105229] [PMID: 31958581]
[97]
Peng Y, Chen L, Ye S, et al. Research and development of drug delivery systems based on drug transporter and nano-formulation. Asian J Pharm Sci 2020; 15(2): 220-36.
[http://dx.doi.org/10.1016/j.ajps.2020.02.004] [PMID: 32373201]
[98]
Zolk O, Fromm MF. Transporter-mediated drug uptake and efflux: important determinants of adverse drug reactions. Clin Pharmacol Ther 2011; 89(6): 798-805.
[http://dx.doi.org/10.1038/clpt.2010.354] [PMID: 21471963]
[99]
Roth M, Obaidat A, Hagenbuch B. OATPs, OATs and OCTs: The organic anion and cation transporters of the SLCO and SLC22A gene superfamilies In: British Journal of Pharmacology. Wiley-Blackwell 2012; 165: pp. (5)1260-87.
[http://dx.doi.org/10.1111/j.1476-5381.2011.01724.x]
[100]
de Jong WH, Borm PJA. Drug delivery and nanoparticles: Applications and hazards. Int J Nanomedicine 2008; 3(2): 133-49.
[http://dx.doi.org/10.2147/IJN.S596] [PMID: 18686775]
[101]
Shao J, Markowitz JS, Bei D, An G. Enzyme- and transporter-mediated drug interactions with small molecule tyrosine kinase inhibitors. J Pharm Sci 2014; 103(12): 3810-33.
[http://dx.doi.org/10.1002/jps.24113] [PMID: 25308414]
[102]
Wu W, Lu Y, Qi J. Editor profiles: Guest editors of special issue on enhancement of dissolution and oral bioavailability of poorly water-soluble drugs. Acta Pharm Sin B 2019; 9(1): 1.
[http://dx.doi.org/10.1016/j.apsb.2019.01.008] [PMID: 31245268]
[103]
Sidat Z, Marimuthu T, Kumar P, et al. Ionic liquids as potential and synergistic permeation enhancers for transdermal drug delivery. Pharmaceutics 2019; 11(2): 96.
[http://dx.doi.org/10.3390/pharmaceutics11020096 ] [PMID: 30813375]
[104]
Mahapatra APK, Patil V, Patil R. Solubility enhancement of poorly soluble drugs by using novel techniques: A comprehensive review. Int J Pharm Tech Res 2020; 13(2): 80-93.
[http://dx.doi.org/10.20902/IJPTR.2019.130211]
[105]
Surender V, Deepika M. Solid lipid nanoparticles: A comprehensive review. J Chem Pharm Res 2016; 8(8)2016; Available online: www.jocpr.com
[106]
Bajaj S, Singla D, Sakhuja N. Stability testing of pharmaceutical products. J Appl Pharm Sci 2021; 2(3)
[http://dx.doi.org/10.7324/JAPS.2012.2322]
[107]
Pokharana M, Vaishnav R, Goyal A, Shrivastava A. Stability testing guidelines of pharmaceutical products. J Drug Deliv Ther 2018; 8(2)
[http://dx.doi.org/10.22270/jddt.v8i2.1564]
[108]
Müller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy. Adv Drug Deliv Rev 2001; 47(1): 3-19.
[http://dx.doi.org/10.1016/S0169-409X(00)00118-6 ] [PMID: 11251242]
[109]
Dengale SJ, Grohganz H, Rades T, Löbmann K. Recent advances in co-amorphous drug formulations. Adv Drug Deliv Rev 2016; 100: 116-25.
[http://dx.doi.org/10.1016/j.addr.2015.12.009] [PMID: 26805787]
[110]
Sandhiya S, Dkhar SA, Surendiran A. Emerging trends of nanomedicine – an overview. Fundam Clin Pharmacol 2009; 23(3): 263-9.
[http://dx.doi.org/10.1111/j.1472-8206.2009.00692.x ] [PMID: 19527298]
[111]
Martinelli C, Pucci C, Battaglini M, Marino A, Ciofani G. Antioxidants and nanotechnology: Promises and limits of potentially disruptive approaches in the treatment of central nervous system diseases. Adv Healthc Mater 2020; 9(3): 1901589.
[http://dx.doi.org/10.1002/adhm.201901589] [PMID: 31854132]

Rights & Permissions Print Cite
Article Metrics
21
1
Wayfinder Image
World Rabies Day
© 2024 Bentham Science Publishers | Privacy Policy